Wilkinson et al. Supplementary Figure 1

DMSO 3h 8h 24h

Bafilomycin
Wilkinson et al. Supplementary Figure 2

The graph shows the relative mRNA levels of SQSTM1/p62 over time and for different treatments. The y-axis represents Relative mRNA Levels, ranging from 0 to 1.5. The x-axis represents different treatments: E64d/PepA with and without addition (+ or -) for NTC1 and CDK11si1 cell lines. The data points are labeled with 72h and 96h time points.
Wilkinson et al. Supplementary Figure 3

The figure illustrates the cell cycle phase distribution of cells treated with E64d/PepA in the presence or absence of NTC1 and CDK11si1 over time periods of 48h and 72h. The cell cycle phases are indicated as G2/M, S, G1, and Sub G1.
**Figure S1.** *Drosophila S2R+* cells expressing GFP-LC3 were exposed to DMSO vehicle for 24 h or bafilomycin for indicated times and then analysed by confocal microscopy.

**Figure S2.** Analysis of p62/SQSTM1 mRNA levels following CDK11 knockdown. MDA-MB-231 cells were transfected with non-targeting control (NTC1) or CDK11si1 siRNA for 72 or 96 h and then treated with either vehicle control or 10 µg/ml E64d/Pepstatin A for 16 h. mRNA levels were analysed by qPCR. Data are presented as mean relative mRNA level ± SD (n = 3) relative to vehicle control in NTC1 transfected cells.

**Figure S3.** Cell cycle analysis following CDK11 knockdown. MDA-MB-231 cells were transfected with non-targeting control (NTC1) or CDK11si1 siRNA for 48 or 72 h and then treated with vehicle control or 10 µg/ml E64d/Pepstatin A for 16 h. Cells were harvested and stained with propidium iodide, and their cell cycle distribution assessed by flow cytometry. Data are presented as the mean percentage of cells in each cell cycle phase ± SD (n = 5).

**Figure S4.** (A) MDA-MB-231 GFP-LC3 cells were transfected with non-targeting control (NTC1) or CDK11si1 siRNA for 72 h and then treated with vehicle control or 50 µM zVAD-fmk for 16 h. The number of cells with overt GFP-LC3 puncta was determined from 10 independent fields. Data are shown as mean percentage of puncta positive cells ± SD (n = 10). (B) zVAD-fmk can inhibit cell death induced by TNFα in MDA-MB-231 cells. Cells were treated with 10 ng/ml TNFα plus 10 µg/ml cycloheximide (CHX) for 30h, in the absence or presence of 50 µM zVAD-fmk.
Adherent and non-adherent cells were collected and processed for PI staining. Cell death is shown as the mean percentage of subG1 positive cells ± SEM (n = 3).